HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing

Background: With the approval of the HIV-1 capsid inhibitor, lenacapavir, capsid sequencing will be required for managing lenacapavir-experienced individuals with detectable viremia. Successful sequence interpretation will require examining new capsid sequences in the context of previously published...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Kaiming, Rhee, Soo-Yon, Tzou, Philip L., Osman, Zachary A., Pond, Sergei L. Kosakovsky, Holmes, Susan P., Shafer, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143361/
https://www.ncbi.nlm.nih.gov/pubmed/37112972
http://dx.doi.org/10.3390/v15040992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143361/
https://www.ncbi.nlm.nih.gov/pubmed/37112972
http://dx.doi.org/10.3390/v15040992

Ejemplares similares